Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aquestive Therapeutics Inc.

6.82
+0.16002.40%
Post-market: 6.850.0300+0.44%16:36 EDT
Volume:1.75M
Turnover:11.80M
Market Cap:825.04M
PE:-9.89
High:6.87
Open:6.68
Low:6.58
Close:6.66
52wk High:7.55
52wk Low:2.12
Shares:120.97M
Float Shares:115.00M
Volume Ratio:0.74
T/O Rate:1.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6897
EPS(LYR):-0.5089
ROE:148.50%
ROA:-31.12%
PB:-11.37
PE(LYR):-13.40

Loading ...

Aquestive Therapeutics Highlights Anaphylm Phase 1 Results at 2025 ACAAI Meeting

Reuters
·
Oct 30

Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET

GlobeNewswire
·
Oct 27

Aquestive Therapeutics Chief Medical Officer Carl N. Kraus Reports Disposal of Common Shares

Reuters
·
Oct 18

Aquestive Therapeutics Inc. Officer Peter E. Boyd Reports Disposal of Common Shares

Reuters
·
Oct 18

Aquestive Therapeutics Broadens Patent Estate for Anaphylm™

THOMSON REUTERS
·
Oct 08

Aquestive Therapeutics Inc - New Patents Extend Anaphylm Protection Into 2037

THOMSON REUTERS
·
Oct 08

Aquestive Therapeutics Secures Two New U.S. Patents for Anaphylm™ Sublingual Epinephrine Film, Extending Protection Through 2037

Reuters
·
Oct 08

Aquestive Therapeutics Inc. Officer Peter E. Boyd Reports Disposal of Common Shares

Reuters
·
Sep 30

Aquestive Therapeutics Inc. CEO Daniel Barber Reports Disposal of Common Shares

Reuters
·
Sep 24

Officer Peter E. Boyd Reports Disposal of Common Shares in Aquestive Therapeutics Inc

Reuters
·
Sep 09

Oppenheimer Adjusts Aquestive Therapeutics Price Target to $8 From $7, Maintains Outperform Rating

MT Newswires Live
·
Sep 08

Aquestive Therapeutics, Inc. : Oppenheimer Raises Target Price to $8 From $7

THOMSON REUTERS
·
Sep 08

Aquestive Therapeutics Shares Rise, FDA Forgos Meeting on Anaphylm

Dow Jones
·
Sep 05

BUZZ-U.S. STOCKS ON THE MOVE- Gap, Aquestive Therapeutics, Lumentum

Reuters
·
Sep 04

Aquestive Therapeutics Up Nearly 19%, On Pace For Largest Percent Increase Since March 2024 -- Data Talk

Dow Jones
·
Sep 04

BUZZ-Aquestive climbs after US FDA says no advisory panel needed for epinephrine film

Reuters
·
Sep 04

BRIEF-Aquestive Therapeutics Announces That FDA Will Not Require An Advisory Committee Meeting To Discuss New Drug Application For Anaphylm™

Reuters
·
Sep 04

Aquestive Therapeutics Announces That FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™

THOMSON REUTERS
·
Sep 04

Aquestive Therapeutics Inc - Pdufa Target Action Date for Anaphylm Is January 31, 2026

THOMSON REUTERS
·
Sep 04

Aquestive Therapeutics Inc. to Participate in Upcoming H.C. Wainwright Global Investor Conference

Reuters
·
Aug 26